|Application ||WB, E|
|Other Accession||NP_057658.2, NP_000786.1|
|Calculated MW||50619 Da|
|Antigen Region||307-336 aa|
|Other Names||D(2) dopamine receptor, Dopamine D2 receptor, DRD2|
|Target/Specificity||This DRD2 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 307-336 amino acids from the C-terminal region of human DRD2.|
|Format||Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification.|
|Storage||Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.|
|Precautions||DRD2 Antibody (C-term) is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase (PubMed:21645528). Positively regulates postnatal regression of retinal hyaloid vessels via suppression of VEGFR2/KDR activity, downstream of OPN5 (By similarity).|
|Cellular Location||Cell membrane; Multi-pass membrane protein. Golgi apparatus membrane; Multi-pass membrane protein|
|Tissue Location||[Isoform 1]: Expressed in the anterior pituitary gland.|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
This gene encodes the D2 subtype of the dopamine receptor. This G-protein coupled receptor inhibits adenylyl cyclase activity. A missense mutation in this gene causes myoclonus dystonia; other mutations have been associated with schizophrenia. Alternative splicing of this gene results in two transcript variants encoding different isoforms. A third variant has been described, but it has not been determined whether this form is normal or due to aberrant splicing.
Verma, V., et al. J. Biol. Chem. 285(45):35092-35103(2010)
Borroto-Escuela, D.O., et al. Biochem. Biophys. Res. Commun. 401(4):605-610(2010)
Stelzel, C., et al. J. Neurosci. 30(42):14205-14212(2010)
Huang, H.Y., et al. J. Formos. Med. Assoc. 109(10):736-739(2010)
Itokawa, M., et al. J. Pharmacol. Sci. 114(1):1-5(2010)
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at email@example.com.